🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

AngioDynamics, Inc. ANGO R2K

Healthcare · Medical Instruments & Supplies · United States
https://www.angiodynamics.com
Company Profile ↓
$13.00
+34.99% 1Y
Mkt Cap$537.15M
P/E-17.11
P/B2.91
52W High$13.66
52W Low$8.40
Book Value$4.16
EPS (TTM)$-0.76

Company Overview

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.07.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • May 2025 Revenue of $292.50M (-3.8% YoY); net profit $-33.99M.
  • Trailing 12 Months Year-on-year growth — revenue +8.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR -2.6%, profit CAGR -9.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-2.57%
1 Year:8.90%

Compounded Profit Growth

5 Years:-9.35%
1 Year:-

Stock Price Performance

1 Year:+34.99%
6 Months:+31.85%
3 Months:+26.95%
1 Month:+7.62%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 87% of range
$8.40 $13.66
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)58.51 · Neutral
Price Performance
1M+7.62%
3M+26.95%
6M+31.85%
1Y+34.99%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -2.6% CAGR over 5 years.
  • Earnings shrank at -9.3% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-17.11
Industry PE
25.41
Forward P/E
-59.09
PEG Ratio
1.41
Book Value
$4.16
Price to Book
2.91
P/S
1.59
EV/EBITDA
-725.25
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-2.57%
Profit 5Y
-9.35%
Revenue (YoY)
8.90%
Earnings (YoY)
-

Profitability & Returns

ROCE
-11.80%
ROE
-17.47%
ROA
-4.68%
Profit Margin
-10.01%
Op Margin
-8.20%
Gross Margin
54.30%
EPS (Latest Qtr)
$-0.19
EPS (TTM)
$-0.76

Balance Sheet & Liquidity

Debt/Equity
0.07
Quick Ratio
1.26
Current Ratio
2.35
Debt
$11.39M
Total Assets
$260.68M
Current Assets
$155.55M
Working Capital
$92.13M

Ownership

Promoter Holding
12.28%
Chg in Prom Hold
-
FII / Inst Holding
94.69%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$537.15M
Total Revenue (TTM)
$313.72M
EBITDA
$-659.00K
Free Cash Flow
$13.94M
Operating Cash Flow
$4.45M
Shares Outstanding
41.32M
Gross Margin
54.30%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ANGO AngioDynamics, Inc. R2K 13.00 -17.11 $537.15M 0.00% -11.80% -17.47% -2.57% -9.35%
2 LLY Eli Lilly and Company SPX 1,152.54 41.02 $1.03T 0.61% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 253.85 29.45 $611.07B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.78 119.40 $432.48B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 425.19 32.02 $386.13B 2.27% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 120.78 34.02 $298.31B 2.86% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 164.50 24.81 $255.12B 1.77% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 534.07 29.33 $198.47B 0.40% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 355.25 24.69 $191.73B 2.84% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Aug 2015Nov 2015Feb 2016May 2016Aug 2016Nov 2016Feb 2017May 2017Aug 2017Nov 2017Feb 2018May 2018Aug 2018Nov 2018Feb 2019May 2019Aug 2019Nov 2019Feb 2020May 2020Aug 2020Nov 2020Feb 2021Aug 2021Nov 2021Feb 2022May 2022Aug 2022Nov 2022Feb 2023Aug 2023Nov 2023Feb 2024Aug 2024Nov 2024Feb 2025May 2025Aug 2025Nov 2025Feb 2026
Revenue --------------------70.22M72.77M71.18M76.97M78.28M73.97M-81.54M85.43M80.71M78.68M79.07M75.18M67.49M-72.00M80.16M75.71M79.43M78.42M
Cost of Revenue -----------------------------------33.15M37.94M33.85M34.65M36.94M
Gross Profit 43.37M45.88M43.53M41.53M45.03M45.01M43.79M42.34M33.04M34.70M37.50M38.62M35.95M40.55M38.16M41.33M38.22M41.54M40.30M30.21M35.76M40.17M38.53M40.14M40.55M38.58M-42.30M45.08M40.50M40.06M40.26M35.86M36.72M-38.86M42.22M41.86M44.78M41.48M
Operating Expenses -----------------------------------45.51M45.85M49.76M47.27M47.91M
Operating Income 212.00K565.00K1.97M-3.57M15.59M5.14M-140.00K1.12M4.86M--6.13M-2.53M-3.67M--828.00K-3.42M-6.24M--5.12M-4.84M-3.74M-8.10M-8.68M-5.29M--13.30M-8.12M-8.93M35.03M-13.12M-199.90M-13.10M--6.65M-3.63M-7.90M-2.49M-6.43M
EBITDA ------------------------------------329.00K2.20M-1.88M3.26M-838.00K
Interest Expense ----------------------------------------
Pretax Income ------------------------------------4.41M-6.11M-10.84M-6.36M-8.07M
Tax Provision ------------------------------------2.00K-60.00K65.00K-5.00K12.00K
Net Income -775.00K-334.00K594.00K-43.08M1.30M13.73M2.89M-12.91M-35.00K249.00K14.02M2.10M-469.00K2.14M796.00K58.87M-1.27M-2.74M-5.71M-157.07M-4.27M-4.27M-3.54M-6.97M-8.35M-4.96M-13.00M-13.00M-8.49M-9.48M45.88M-29.05M-187.74M-12.80M--4.41M-6.05M-10.90M-6.35M-8.08M
Diluted EPS -0.02-0.010.02-1.190.040.370.08-0.350.000.010.370.06-0.010.060.021.54-0.03-0.07-0.15-4.14-0.11-0.11-0.09-0.18-0.21-0.13--0.33-0.21-0.241.15-0.72-4.67-0.31--0.11-0.15-0.26-0.15-0.19
R&D Expense 6.13M6.18M5.81M-6.71M5.91M5.95M-6.44M6.11M6.46M-7.37M7.08M6.92M-6.29M7.76M8.39M-9.01M9.71M8.56M7.39M8.20M7.28M-8.33M6.84M6.85M7.94M8.66M8.19M6.29M6.43M6.91M-6.42M7.77M7.08M

Profit & Loss (Annual)

Figures in USD.

Metric May 2010May 2011May 2012May 2013May 2014May 2015May 2016May 2017May 2018May 2019May 2020May 2021May 2022May 2023May 2024May 2025
Revenue 216.03M215.62M221.92M341.92M354.43M356.53M353.89M269.79M261.65M270.63M264.16M291.01M316.22M338.75M303.91M292.50M
Cost of Revenue ------------150.49M164.51M149.22M134.79M
Gross Profit 126.97M125.57M125.31M168.51M180.17M175.80M174.32M143.95M143.86M156.00M150.27M156.79M165.73M174.25M154.70M157.71M
Operating Expenses ------------183.95M192.93M188.54M181.77M
Operating Income 20.87M11.90M-5.24M5.24M10.49M-3.45M1.02M-11.18M-14.17M-9.40M-167.10M-35.28M-18.22M-18.68M-33.84M-24.06M
EBITDA ------------11.13M12.19M-6.13M1.74M
Interest Expense ------------688.00K2.70M--
Pretax Income -------------29.95M-54.44M-191.64M-34.03M
Tax Provision -------------3.40M-2.00M-7.29M-39.00K
Net Income 12.31M8.08M-5.33M-1.05M2.35M-3.39M-43.59M5.01M16.34M61.34M-166.79M-31.55M-26.55M-52.44M-184.35M-33.99M
Diluted EPS 0.500.32-0.20-0.030.07-0.09-1.210.140.441.64-4.39-0.82-0.68-1.33-4.59-0.83
R&D Expense 19.27M21.37M20.51M26.09M28.12M26.59M25.05M24.15M24.34M28.26M29.68M36.39M30.74M29.88M31.51M26.22M

Balance Sheet (Annual)

Figures in USD.

Metric May 2009May 2010May 2011May 2012May 2013May 2014Aug 2014Nov 2014Feb 2015May 2015Aug 2015Nov 2015Feb 2016May 2016May 2017May 2018May 2019May 2020May 2021May 2022May 2023May 2024May 2025
Total Assets --437.31M719.90M790.56M798.58M796.17M798.73M783.39M773.06M772.00M760.44M753.61M726.19M707.96M705.47M836.44M594.21M561.44M552.75M532.64M317.67M280.14M
Current Assets -------------------143.34M163.54M193.25M168.32M
Cash & Equivalents 27.91M58.76M45.98M23.74M16.11M18.39M---18.39M---32.33M47.54M74.10M227.64M54.44M48.16M28.82M44.62M76.06M55.89M
Inventory -------------------51.39M55.33M60.62M62.01M
Receivables -------------------52.30M52.83M43.61M42.89M
Total Liabilities --31.68M196.60M264.24M261.69M256.58M255.49M239.82M227.96M224.82M212.72M202.82M218.97M192.93M162.88M221.62M139.34M121.98M128.26M154.34M112.08M97.17M
Current Liabilities --25.40M53.77M62.92M65.94M63.35M57.10M59.50M60.52M60.80M60.09M61.63M66.73M71.52M57.30M73.30M51.45M57.58M74.32M83.83M91.16M76.20M
Long Term Debt --6.28M142.50M135.00M137.66M--------91.32M86.62M124.41M--25.00M49.82M--
Total Debt -------------------33.78M64.58M4.73M-
Total Equity 372.19M391.35M405.64M523.31M526.32M536.88M539.59M543.24M543.57M545.10M547.18M547.73M550.80M507.23M515.03M542.60M614.82M454.87M439.46M424.49M378.30M205.59M182.97M
Shares Outstanding -------------------39.54M39.98M40.80M41.61M

Cash Flows (Annual)

Figures in USD.

Metric May 2010May 2011May 2012May 2013May 2014May 2015May 2016May 2017May 2018May 2019May 2020May 2021May 2022May 2023May 2024May 2025
Operating Cash Flow 39.96M33.87M11.60M26.65M24.68M25.68M45.22M55.74M41.29M37.44M-14.55M24.09M-7.19M78.00K-28.16M-10.13M
Investing Cash Flow -11.78M-48.62M-176.23M-22.24M-16.45M-12.74M-7.57M-2.55M-3.66M82.55M-63.34M-13.71M-19.31M-9.75M123.72M-10.18M
Financing Cash Flow 2.72M1.92M142.34M-6.29M-14.02M-10.46M-23.66M-37.98M-11.55M33.93M-95.24M-16.99M7.68M25.42M-64.25M-255.00K
Capital Expenditure -5.04M-2.96M-2.49M-12.12M-11.17M-11.38M-2.33M-3.00M-2.39M-3.12M-7.24M-5.19M-4.30M-4.35M-5.77M-4.46M
Free Cash Flow 34.92M30.91M9.11M14.53M13.51M14.30M42.89M52.74M38.90M34.32M-21.79M18.91M-11.49M-4.27M-33.93M-14.59M
Net Change in Cash -------------18.82M15.75M31.31M-20.56M
Share Buybacks --2.10M000013.56M00---001.67M
Dividends Paid --000-----------

Ratios (Annual)

Figures in %.

Metric May 2010May 2011May 2012May 2013May 2014May 2015May 2016May 2017May 2018May 2019May 2020May 2021May 2022May 2023May 2024May 2025
Gross Margin % 58.8%58.2%56.5%49.3%50.8%49.3%49.3%53.4%55.0%57.6%56.9%53.9%52.4%51.4%50.9%53.9%
Operating Margin % 9.7%5.5%-2.4%1.5%3.0%-1.0%0.3%-4.1%-5.4%-3.5%-63.3%-12.1%-5.8%-5.5%-11.1%-8.2%
Net Margin % 5.7%3.7%-2.4%-0.3%0.7%-1.0%-12.3%1.9%6.2%22.7%-63.1%-10.8%-8.4%-15.5%-60.7%-11.6%
ROE % 3.1%2.0%-1.0%-0.2%0.4%-0.6%-8.6%1.0%3.0%10.0%-36.7%-7.2%-6.3%-13.9%-89.7%-18.6%
ROCE % -2.9%-0.8%0.7%1.4%-0.5%0.2%-1.8%-2.2%-1.2%-30.8%-7.0%-3.8%-4.2%-14.9%-11.8%

Shareholding Pattern

Insiders
12.28%
Institutions
94.69%
Public Float
107.95%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.92% 3.69M $48.67M
2 Point72 Asset Management, L.P. 7.70% 3.18M $42.02M
3 Systematic Financial Management, L.P. 5.94% 2.45M $32.40M
4 Broadfin Holdings LLC 5.01% 2.07M $27.33M
5 Armistice Capital, LLC 4.52% 1.87M $24.68M
6 Vanguard Capital Management LLC 4.18% 1.73M $22.80M
7 Royce & Associates LP 3.70% 1.53M $20.19M
8 Weber Capital Management LLC /ADV 3.32% 1.37M $18.13M
9 State Street Corporation 3.23% 1.33M $17.61M
10 Bastion Asset Management Inc. 3.18% 1.31M $17.34M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ANGO

Yahoo Finance ue, 14 Jul 2026

AngioDynamics Inc (ANGO) Q4 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges

AngioDynamics Inc (ANGO) reports robust revenue increases driven by MedTech and NanoKnife segments, despite facing net losses and competitive market pressures.

Yahoo Finance ue, 14 Jul 2026

AngioDynamics Q4 Earnings Call Highlights

AngioDynamics (NASDAQ:ANGO) reported higher fiscal fourth-quarter and full-year revenue, driven by continued growth in its med tech portfolio, while management said the company remains focused on balancing investment in clinical programs wi…

Yahoo Finance ue, 14 Jul 2026

AngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of +36.36% and +7.61%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?

Yahoo Finance ue, 14 Jul 2026

AngioDynamics Tops Revenue Forecasts and Raises Sales Outlook for Fiscal 2027 (ANGO)

AngioDynamics Inc. (NASDAQ:ANGO) delivered stronger-than-expected fourth-quarter results on Tuesday, beating Wall Street forecasts for both revenue and adjusted earnings while issuing an upbeat sales outlook for fiscal 2027.…

Yahoo Finance ue, 14 Jul 2026

AngioDynamics: Fiscal Q4 Earnings Snapshot

LATHAM, N.Y. (AP) — AngioDynamics Inc. (ANGO) on Tuesday reported a loss of $11.4 million in its fiscal fourth quarter. On a per-share basis, the Latham, New York-based company said it had a loss of 27 cents. For the year, the company rep…

Yahoo Finance ue, 14 Jul 2026

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

LATHAM, N.Y., July 14, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improvin…

ANGO — Frequently Asked Questions

What is the current share price of AngioDynamics, Inc. (ANGO)?

As of 2026-07-14 21:23 PDT, AngioDynamics, Inc. (ANGO) trades at $13.00 on NasdaqGS. Its 52-week range is $8.40 to $13.66.

What is the market capitalisation of ANGO?

AngioDynamics, Inc. (ANGO) has a market capitalisation of $537.15M on NasdaqGS.

What is the P/E ratio of ANGO?

ANGO trades at a trailing price-to-earnings (P/E) ratio of -17.11. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.91.

What is the return on equity (ROE) of ANGO?

ANGO has a return on equity (ROE) of -17.47%. Its return on capital employed (ROCE) is -11.80%.

Is ANGO a good stock to buy?

This page provides a data-driven analysis of AngioDynamics, Inc. (ANGO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space